Abstracts » Health

Experts point to lessons learned from controversy over rofecoxib safety

Article Abstract:

Patients and physicians have raised concern regarding the safety of other drugs that preferentially inhibit the cyclooxygenase-2 COX-2) enzyme which was pulled from the market due to life-threatening adverse cardiovascular events. It is suggested that extensive pharmacoepidemiological studies for drugs, which include examining a drug's effects over a longer period and address a more representative patient population than is seen in randomized trials.

Product quality, Cardiovascular diseases, Complications and side effects, Risk factors, Quality management, Pharmaceutical research, Rofecoxib

---

1918 flu vaccine effective in mice

Article Abstract:

Scientists from the National Institute of Health, the Centers for Disease Control and Prevention and the Mount Sinai School of Medicine found that all mice survived an intranasal challenge of live, reconstructed 1981 virus given 14 days after immunization with DNA vaccine. The vaccine consisted of a vector expressing the virus's gene for hemagglutinin, a protein that allows the flu virus to bind cell and cause infection.

Patient outcomes, Influenza vaccines, Influenza, Clinical report

---

Cancer agents show first-line potential

Article Abstract:

The trial results for the safety and efficacy of some of agents such as arsenic trioxide for acute promyelocytic leukemia, desatinib for chronic myelogenous leukemia and bevacizumab for renal cell carcinoma as potential new first-line treatments for patients with cancer is discussed.

Dosage and administration, Chronic myeloid leukemia, Carcinoma, Renal cell, Renal cell carcinoma, Bevacizumab

Some parts © 2012 Advameg, Inc.